Bristol-Myers Squibb Company / Inhibitex Inc.

Hepatitis C (HCV)

Competitive Landscape

INX-189 (BMS-986094) was an NS5B nucleotide polymerase inhibitor terminated 2012 due to cardiotoxicity; assessed against the HCV landscape that subsequently emerged, the asset faced no commercial path across four DAA MOA classes. NS5B nucleotide polymerase inhibitors (class where INX-189 sat): Sovaldi (sofosbuvir, Gilead) became the class-defining backbone and central component of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir), and Vosevi (sofosbuvir/velpatasvir/voxilaprevir), generating roughly $19B at 2015 peak; no competing nucleotide NS5B survived clinical development. NS5A inhibitors: Daklinza (daclatasvir, BMS), Harvoni ledipasvir component (Gilead), Mavyret pibrentasvir component (AbbVie), Epclusa velpatasvir component - all approved pan-genotypic or genotype-specific. NS3/4A protease inhibitors: Mavyret glecaprevir (AbbVie), Vosevi voxilaprevir (Gilead), Olysio (simeprevir, J&J discontinued), Incivek (telaprevir, Vertex discontinued). Pan-genotypic fixed-dose combinations now dominate: Mavyret (glecaprevir/pibrentasvir, AbbVie, 8-week therapy, roughly $2B 2023) and Epclusa (sofosbuvir/velpatasvir, Gilead) command >95% of new patient starts, with 95%+ SVR12 cure rates. Commercial threat and ultimate asset outcome: BMS-986094 was discontinued before approval; the HCV market matured into a curative one-time therapy model with declining treated population and no room for second-wave nucleotide polymerase entrants.